Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
STRIDES PHARMA SCIENCE ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
STRIDES PHARMA SCIENCE Mar-23 |
ADCOCK INGRAM Jun-14 |
STRIDES PHARMA SCIENCE/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 392 | 316 | - | |
Low | Rs | 263 | 228 | - | |
Sales per share (Unadj.) | Rs | 408.5 | 94.0 | - | |
Earnings per share (Unadj.) | Rs | -25.6 | -23.7 | - | |
Cash flow per share (Unadj.) | Rs | 1.4 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 1.50 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 242.8 | 73.8 | - | |
Shares outstanding (eoy) | m | 90.30 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.8 | 2.9 | 27.7% | |
Avg P/E ratio | x | -12.8 | -11.5 | 111.7% | |
P/CF ratio (eoy) | x | 239.6 | -13.9 | -1,729.6% | |
Price / Book Value ratio | x | 1.4 | 3.7 | 36.6% | |
Dividend payout | % | -5.9 | 0 | - | |
Avg Mkt Cap | Rs m | 29,603 | 45,919 | 64.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 7,320 | 2,882 | 254.0% | |
Avg. sales/employee | Rs Th | 0 | 3,696.8 | - | |
Avg. wages/employee | Rs Th | 0 | 671.3 | - | |
Avg. net profit/employee | Rs Th | 0 | -931.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 36,884 | 15,870 | 232.4% | |
Other income | Rs m | 1,352 | 111 | 1,216.7% | |
Total revenues | Rs m | 38,236 | 15,982 | 239.3% | |
Gross profit | Rs m | 830 | -2,750 | -30.2% | |
Depreciation | Rs m | 2,433 | 685 | 355.1% | |
Interest | Rs m | 2,611 | 430 | 607.5% | |
Profit before tax | Rs m | -2,862 | -3,754 | 76.2% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -553 | 235 | -235.8% | |
Profit after tax | Rs m | -2,309 | -3,999 | 57.7% | |
Gross profit margin | % | 2.2 | -17.3 | -13.0% | |
Effective tax rate | % | 19.3 | -6.2 | -309.2% | |
Net profit margin | % | -6.3 | -25.2 | 24.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 31,353 | 11,624 | 269.7% | |
Current liabilities | Rs m | 29,902 | 6,540 | 457.2% | |
Net working cap to sales | % | 3.9 | 32.0 | 12.3% | |
Current ratio | x | 1.0 | 1.8 | 59.0% | |
Inventory Days | Days | 71 | 111 | 64.1% | |
Debtors Days | Days | 129 | 124 | 103.8% | |
Net fixed assets | Rs m | 31,300 | 6,775 | 462.0% | |
Share capital | Rs m | 903 | 74 | 1,225.5% | |
Net worth | Rs m | 21,928 | 12,457 | 176.0% | |
Long term debt | Rs m | 11,398 | 4,377 | 260.4% | |
Total assets | Rs m | 63,734 | 23,531 | 270.8% | |
Interest coverage | x | -0.1 | -7.7 | 1.2% | |
Debt to equity ratio | x | 0.5 | 0.4 | 147.9% | |
Sales to assets ratio | x | 0.6 | 0.7 | 85.8% | |
Return on assets | % | 0.5 | -15.2 | -3.1% | |
Return on equity | % | -10.5 | -32.1 | 32.8% | |
Return on capital | % | -0.8 | -19.8 | 3.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 444 | 1,355 | 32.8% | |
From Investments | Rs m | 3,025 | -416 | -727.2% | |
From Financial Activity | Rs m | -2,139 | 3,973 | -53.8% | |
Net Cashflow | Rs m | 1,328 | 4,912 | 27.0% |
Compare STRIDES PHARMA SCIENCE With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare STRIDES PHARMA SCIENCE With: MANKIND PHARMA GLAND PHARMA BAL PHARMA JUBILANT PHARMOVA PFIZER
Indian share markets continued the momentum as the session progressed and ended the higher.